AltruBio   Report issue

For profit Phase 1 Phase 2
Founded: Los Altos CA United States (2000)
Status: Left NME R&D (2023)

Organization Overview

First Clinical Trial
2011
NCT01466569
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

AbGenmics B.V. Taiwan Branch | AbGenomics B.V Taiwan Branch | AbGenomics International, Inc. | AltruBio Inc.

Active Ingredients

Drugs in Phase 2 Trials (3)

allogeneic hematopoietic stem cells (Hemacord) (4 trials)

altb-268 (2 trials)

neihulizumab (3 trials)

Drugs in Phase 1 Trials (1)

abgn-107 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 2)

Arthritis, Psoriatic (Phase 2)

Biliary Tract Neoplasms (Phase 1)

Colitis (Phase 2)

Colitis, Ulcerative (Phase 2)

Graft vs Host Disease (Phase 1)

Psoriasis (Phase 2)

Stomach Neoplasms (Phase 1)

Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 11
  • # of Trial APIs: 4